New Immunosuppressive Modalities and Anti-rejection Approaches in Organ Transplantation

This book brings together reviews from acknowledged experts on current trends in the treatment of transplant rejection. It provides a glimpse into the future of immunosuppressive therapy and an advance into the understanding of biological anti-rejection host immunomodulation. It offers the hope that rejection may either be prevented or treated more safely and effectively than ever before. The reviews cover many diverse modalities, including rapamycin, RS-61443, brequinar sodium, 15-deoxyspergualin, mizoribine, azaspirines and leflunomide, and describe the exploration of the mechanistic aspects and insights into the use of monoclonal antibodies, synthetic peptides, recombinant toxins and fusion proteins.